The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.

[1]  S. Vaseghi,et al.  The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines , 2021, Molecular Biology Reports.

[2]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[3]  S. Wiemann,et al.  Abrogating GPT2 in triple‐negative breast cancer inhibits tumor growth and promotes autophagy , 2020, International journal of cancer.

[4]  Yiqing Zhao,et al.  5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers , 2020, Cancer Research.

[5]  Ning Wang,et al.  Glutamic-Pyruvic Transaminase 1 Facilitates Alternative Fuels for Hepatocellular Carcinoma Growth—A Small Molecule Inhibitor, Berberine , 2020, Cancers.

[6]  K. Tew,et al.  Oxidative Stress in Cancer. , 2020, Cancer cell.

[7]  J. Waldron,et al.  Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. , 2020, Oral oncology.

[8]  A. Mai,et al.  Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer , 2020, Frontiers in Oncology.

[9]  N. Lee,et al.  A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. , 2020, International journal of radiation oncology, biology, physics.

[10]  G. Ke,et al.  Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation , 2019, Molecular Cancer Therapeutics.

[11]  M. Najafi,et al.  Targets for improving tumor response to radiotherapy. , 2019, International immunopharmacology.

[12]  K. Machado,et al.  Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yanni Peng,et al.  Glutamine Synthetase Promotes Radiation Resistance via Facilitating Nucleotide Metabolism and Subsequent DNA Damage Repair. , 2019, Cell reports.

[14]  P. Gestraud,et al.  Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome , 2019, EBioMedicine.

[15]  Y. See,et al.  Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1) , 2019, Cellular and Molecular Neurobiology.

[16]  D. Rubinsztein,et al.  Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A , 2019, Cell metabolism.

[17]  Wei-Wei Jiang,et al.  The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer , 2018, Journal of Hematology & Oncology.

[18]  W. Koom,et al.  Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. , 2018, Gynecologic oncology.

[19]  Dejan Juric,et al.  Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Ahmad,et al.  The Role of Sirtuins in Antioxidant and Redox Signaling. , 2017, Antioxidants & redox signaling.

[21]  Changhao Chen,et al.  HIF‐2α regulates non‐canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma , 2017, Journal of cellular and molecular medicine.

[22]  K. Kinzler,et al.  Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer , 2016, Nature Communications.

[23]  C. Ferreira,et al.  A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I , 2016, Cancer Chemotherapy and Pharmacology.

[24]  J. Pignon,et al.  Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Liao,et al.  RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint. , 2014, Anticancer Research.

[26]  D. Erdmann,et al.  Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.

[27]  Jie Zhou,et al.  Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. , 2013, Biochimica et biophysica acta.

[28]  K. Harrington,et al.  The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[29]  Gregory Stephanopoulos,et al.  The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.

[30]  Xiaoling Xu,et al.  SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. , 2013, Cancer cell.

[31]  J. Maris,et al.  ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. , 2012, Cancer cell.

[32]  H. Aburatani,et al.  Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. , 2012, Cancer cell.

[33]  T. Pandita,et al.  The Proteasome Activator PA200 Regulates Tumor Cell Responsiveness to Glutamine and Resistance to Ionizing Radiation , 2012, Molecular Cancer Research.

[34]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[35]  I. Cotgreave,et al.  Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. , 2009, International journal of molecular medicine.

[36]  Jennifer E. Van Eyk,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2016 .

[37]  N. Hay,et al.  Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.

[38]  S. Weitzman,et al.  p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc , 2008, Oncogene.

[39]  Ching-Chow Chen,et al.  Akt Phosphorylation of p300 at Ser-1834 Is Essential for Its Histone Acetyltransferase and Transcriptional Activity , 2005, Molecular and Cellular Biology.

[40]  J. Chen,et al.  Role of Akt/protein kinase B in the activity of transcriptional coactivator p300 , 2004, Cellular and Molecular Life Sciences CMLS.

[41]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.